Use of GLP-1 receptor agonists and dual agonists in patients with inflammatory bowel disease
DOI:
https://doi.org/10.12775/QS.2026.77.76265Keywords
Inflammatory Bowel Disease, GLP-1 Receptor Agonists, Obesity, Tirzepatide, Mucosal HealingAbstract
Background: Obesity represents a growing epidemiological problem in patients with inflammatory bowel disease (IBD), affecting up to 40% of patients. Excess adipose tissue worsens clinical prognosis, sustains systemic inflammation, and accelerates the loss of response to biological therapy.
Aim: The aim of this study was to summarize current knowledge regarding the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists (tirzepatide) in this patient group.
Materials and methods: PubMed Scopus, Web of Science, and Cochrane Library databases were searched from their inception through September 2026 using a combination of relevant keywords. A total of 20 studies were included in the review.
Results: Incretin-based therapies demonstrate immunomodulatory and intestinal barrier–protective effects. Real-world studies and meta-analyses show that semaglutide, liraglutide, and tirzepatide induce significant weight loss (6–12%+), reduce C-reactive protein levels, hospitalization rates, corticosteroid use, and the risk of IBD-related surgery by up to 55%. These agents are generally well tolerated and are not associated with an increased risk of IBD exacerbations. Delayed gastric emptying remains an important consideration, particularly in patients receiving oral thiopurines due to the potential for altered drug pharmacokinetics and hepatotoxicity.
Conclusions: GLP-1 and GIP/GLP-1 agonists represent a highly promising, safe adjunctive therapy for patients with IBD and metabolic disorders. Results from ongoing randomized controlled trials will allow for the definitive establishment of their position in gastroenterological guidelines.
References
1. Yang, M., Huo, Y., Liu, Z., Bai, G., He, D., & Zhang, L. (2025). The role of GLP-1 receptor agonists in IBD-related surgery and IBD-related complications of inflammatory bowel disease among patients with metabolic comorbidities: a systematic review and meta-analysis. Frontiers in medicine, 12, 1621958. https://doi.org/10.3389/fmed.2025.1621958
2. Ramos Belinchón, C., Martínez-Lozano, H., Serrano Moreno, C., Hernández Castillo, D., Lois Chicharro, P., Ferreira Ocampo, P., Marín-Jiménez, I., Bretón Lesmes, I., & Menchén, L. (2024). Effectiveness and safety of a GLP-1 agonist in obese patients with inflammatory bowel disease. Revista espanola de enfermedades digestivas, 116(9), 478–483. https://doi.org/10.17235/reed.2024.10305/2024
3. Fernando, S., Zhao, J., Josloff, K., Zubair, N., Desai, A., Shivashankar, R., Kozuch, P. L., Choudhary, C., Lichtenstein, G., & Sehgal, P. (2026). Glucagon like peptide 1 receptor agonists in patients with inflammatory bowel disease: safety, clinical effectiveness and anti-inflammatory mechanisms. Frontiers in gastroenterology (Lausanne, Switzerland), 5, 1864456. https://doi.org/10.3389/fgstr.2026.1864456
4. Maracle, B., Quan, S., Hamilton, P., Shaikh, A., Hazra, D., Lorenzetti, D. L., Gold, S. L., Raman, M., & St-Pierre, J. (2026). Systematic Review: Efficacy, Safety and Metabolic Outcomes of GLP-1 Receptor Agonists in Inflammatory Bowel Disease. Alimentary pharmacology & therapeutics, 63(1), 17–39. https://doi.org/10.1111/apt.70485
5. Clarke, L., Passam, R. T., Falahee, B., Jirapinyo, P., Allegretti, J. R., & Kelly, C. R. (2025). Tolerability and Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Inflammatory Bowel Disease. Digestive diseases and sciences, 70(7), 2426–2432. https://doi.org/10.1007/s10620-025-08964-6
6. Weng, J., Alizadeh, M., & Friedman, S. (2025). Glucagon-Like Peptide-1 Receptor Agonist Therapy Does Not Increase Gastrointestinal Adverse Events in Patients with Inflammatory Bowel Disease. Digestive diseases and sciences, 70(10), 3476–3484. https://doi.org/10.1007/s10620-025-09344-w
7. Desai, A., Khataniar, H., Tabaku, F., Hashash, J. G., Farraye, F. A., & Kochhar, G. S. (2026). Efficacy of tirzepatide for weight loss and it's comparative effectiveness to weight loss surgery in inflammatory bowel disease. Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 45(3), 564–575. https://doi.org/10.1007/s12664-025-01835-y
8. Colwill, M., Povlsen, S., Pollok, R., Patel, K., Goodhand, J., Ahmad, T., & Honap, S. (2025). Glucagon-like peptide-1 (GLP-1) receptor agonists in inflammatory bowel disease: mechanisms, clinical implications, and therapeutic potential. Journal of Crohn's & colitis, 19(9), jjaf167. https://doi.org/10.1093/ecco-jcc/jjaf167
9. Levine, J., Lee, Y. A., Pham, A., Guo, J., Dai, H., Radwan, R. M., Bian, J., Novikov, A., & Sheer, A. (2025). Effect of Injectable Dual and Single Agonist Glucagon-Like Peptide-1 Based Therapy on Inflammatory Bowel Disease Activity Among Patients with Obesity. medRxiv : the preprint server for health sciences, 2025.11.13.25340005. https://doi.org/10.1101/2025.11.13.25340005
10. Anderson, S. R., Ayoub, M., Coats, S., McHenry, S., Tan, T., & Deepak, P. (2025). Safety and Effectiveness of Glucagon-like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease. The American journal of gastroenterology, 120(5), 1152–1155. https://doi.org/10.14309/ajg.0000000000003208
11. St-Pierre, J., Klein, J., Choi, N. K., Fear, E., Pannain, S., & Rubin, D. T. (2024). Efficacy and Safety of GLP-1 Agonists on Metabolic Parameters in Non-diabetic Patients with Inflammatory Bowel Disease. Digestive diseases and sciences, 69(12), 4437–4445. https://doi.org/10.1007/s10620-024-08720-2
12. Alharbi S. H. (2024). Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. Therapeutic advances in endocrinology and metabolism, 15, 20420188231222367. https://doi.org/10.1177/20420188231222367
13. Wang, W., Zhang, C., Zhang, H., Li, L., Fan, T., & Jin, Z. (2023). The alleviating effect and mechanism of GLP-1 on ulcerative colitis. Aging, 15(16), 8044–8060. https://doi.org/10.18632/aging.204953
14. Hunt, J. E., Holst, J. J., Jeppesen, P. B., & Kissow, H. (2021). GLP-1 and Intestinal Diseases. Biomedicines, 9(4), 383. https://doi.org/10.3390/biomedicines9040383
15. Saadoun, A. A., Abdelsattar, A. H., Elsaid, A. H., Abdelaleam, E. A., Abdelkader, H. K., Ibrahim, H. M., Saad, M. S., Ellawi, M. S., Elsaid, R. E., Maghrabia, A., Ibrahim, D., & Ramadan, N. M. (2025). Repurposing liraglutide to the management of DSS-induced colitis: a potential for promoting autophagy. Naunyn-Schmiedeberg's archives of pharmacology, 398(12), 17173–17185. https://doi.org/10.1007/s00210-025-04339-w
16. Klein, J. A., St-Pierre, J., Choi, D., Lopez, J., & Rubin, D. T. (2024). Dramatic Changes in Thiopurine Metabolite Levels in a Patient With Inflammatory Bowel Disease Treated With Tirzepatide for Weight Loss. ACG case reports journal, 11(11), e01544. https://doi.org/10.14309/crj.0000000000001544
17. Shneyderman, M., Freid, H., Kohler, D., Peraza, J., Haskey, N., Abbott, E., Kornbluth, A., Raman, M., & Gold, S. (2024). Management of Overweight and Obesity in Patients With Inflammatory Bowel Disease. Gastroenterology & hepatology, 20(12), 712–722.
18. Villumsen, M., Schelde, A. B., Jimenez-Solem, E., Jess, T., & Allin, K. H. (2021). GLP-1 based therapies and disease course of inflammatory bowel disease. EClinicalMedicine, 37, 100979. https://doi.org/10.1016/j.eclinm.2021.100979
19. Alqinai, B., Adeniran, O., Adekolu, A., & Gayam, S. (2026). Semaglutide-Induced Symptomatic Remission in Ulcerative Colitis. ACG case reports journal, 13(4), e02070. https://doi.org/10.14309/crj.0000000000002070
20. Drucker D. J. (2026). The expanding landscape of GLP-1 medicines. Nature medicine, 32(1), 47–57. https://doi.org/10.1038/s41591-025-04124-5
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Michał Antoni Dróżdż, Maria Marcak, Weronika Nowicka, Anna Kożuch, Emilia Rymarczyk

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 200
Number of citations: 0